<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04756427</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00264457</org_study_id>
    <nct_id>NCT04756427</nct_id>
  </id_info>
  <brief_title>Sodium Citrate 4% Locking Solution for Children Requiring Home Parenteral Nutrition</brief_title>
  <official_title>Sodium Citrate 4% Locking Solution for Children Requiring Home Parenteral Nutrition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study an open label prospective observational cohort study to evaluate the safety and&#xD;
      efficacy of sodium citrate 4% locking solution in preventing central line associated blood&#xD;
      stream infection in children requiring long term central venous catheters for home parenteral&#xD;
      nutrition. Sodium citrate 4% is FDA-approved for dialysis catheters, but has not been&#xD;
      formally evaluated for use in tunneled catheters for parenteral nutrition. The rate of&#xD;
      central line-associated bloodstream infection (CLABSI) and other potential adverse events&#xD;
      will be monitored for 12 months, with the option to remain in the study for a longer period&#xD;
      of time.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this prospective observational cohort study of pediatric patients requiring home&#xD;
      parenteral nutrition for intestinal failure, participants will be enrolled from the pediatric&#xD;
      intestinal rehabilitation clinic, and data collection will be obtained from the electronic&#xD;
      medical record. Participant will receive daily sodium citrate 4% catheter locking solution&#xD;
      for CLABSI prophylaxis, instead of heparin locks. Participants will be monitored for 12&#xD;
      months for adverse events, including CLABSI. Participants will have the same routine&#xD;
      laboratory schedule and monthly outpatient follow up. After 12 months, participants will be&#xD;
      given the option to continue to use sodium citrate 4% locks after the initial study period if&#xD;
      no serious adverse events have occurred. The investigators anticipate enrolling 10-15&#xD;
      participants per year and anticipate enrollment to continue for 3-5 years.&#xD;
&#xD;
      Sodium citrate locks: 3 ml vials of locking solution will be prepared by the infusion&#xD;
      pharmacy using commercially available 4% sodium citrate IV fluid (available in 500 ml bags).&#xD;
      The sodium citrate locks will be instilled into the central catheter daily during the period&#xD;
      that parenteral nutrition is not infusing, and will be withdrawn and disposed of prior to&#xD;
      resuming infusion of parenteral nutrition. If subjects are hospitalized, sodium citrate locks&#xD;
      will be temporarily held during the duration of the inpatient stay, and will be resumed once&#xD;
      the participant is discharged home.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">June 2027</completion_date>
  <primary_completion_date type="Anticipated">October 2026</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective cohort after intervention.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Central line-associated bloodstream infection (CLABSI) rate</measure>
    <time_frame>12 months</time_frame>
    <description>Frequency of fever with positive central line blood culture events per central line days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Central venous catheter thrombus rate</measure>
    <time_frame>12 months</time_frame>
    <description>Central line thrombus events requiring anti-coagulation treatment per central line days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central line removal rate</measure>
    <time_frame>12 months</time_frame>
    <description>Central line removal events (infection or other dysfunction) per central line days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of serious adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>Serious adverse events will be assessed with number of hospitalizations for any reason.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>CLABSI - Central Line Associated Bloodstream Infection</condition>
  <arm_group>
    <arm_group_label>Sodium citrate 4%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All enrolled participants will received the daily sodium citrate 4% locking solution for CLABSI prophylaxis intervention and be observed prospectively for adverse events</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Citrate 4% Inj Syringe 3Ml</intervention_name>
    <description>3 ml of sodium citrate 4% locking solution instilled into the central catheter daily during the period that parenteral nutrition is not infusing, and will be withdrawn and disposed of prior to resuming infusion of parenteral nutrition</description>
    <arm_group_label>Sodium citrate 4%</arm_group_label>
    <other_name>ANDA BA125608 / Sodium Citrate 4% w/v Anticoagulant Solution USP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pediatric patients (&lt;18 years)&#xD;
&#xD;
          -  requiring long-term (&gt;3 months) home parenteral nutrition due to intestinal&#xD;
             failure/short bowel syndrome&#xD;
&#xD;
          -  has had at least one central line-associated blood stream infection&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  known cardiac arrhythmias&#xD;
&#xD;
          -  hypersensitivity to citrate&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  receiving continuous parenteral nutrition (infusing over 24 hours)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Darla Shores, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Darla Shores, MD</last_name>
    <phone>410-955-8769</phone>
    <email>dshores1@jhmi.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Darla Shores, MD</last_name>
      <phone>410-955-8769</phone>
      <email>dshores1@jhmi.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Passero BA, Zappone P, Lee HE, Novak C, Maceira EL, Naber M. Citrate versus heparin for apheresis catheter locks: an efficacy analysis. J Clin Apher. 2015 Feb;30(1):22-7. doi: 10.1002/jca.21346. Epub 2014 Aug 13.</citation>
    <PMID>25132635</PMID>
  </reference>
  <reference>
    <citation>Grudzinski L, Quinan P, Kwok S, Pierratos A. Sodium citrate 4% locking solution for central venous dialysis catheters--an effective, more cost-efficient alternative to heparin. Nephrol Dial Transplant. 2007 Feb;22(2):471-6. Epub 2006 Oct 25.</citation>
    <PMID>17065193</PMID>
  </reference>
  <reference>
    <citation>Pittiruti M, Bertoglio S, Scoppettuolo G, Biffi R, Lamperti M, Dal Molin A, Panocchia N, Petrosillo N, Venditti M, Rigo C, DeLutio E. Evidence-based criteria for the choice and the clinical use of the most appropriate lock solutions for central venous catheters (excluding dialysis catheters): a GAVeCeLT consensus. J Vasc Access. 2016 Nov 2;17(6):453-464. doi: 10.5301/jva.5000576. Epub 2016 Aug 1. Review.</citation>
    <PMID>27516141</PMID>
  </reference>
  <reference>
    <citation>Weijmer MC, Debets-Ossenkopp YJ, Van De Vondervoort FJ, ter Wee PM. Superior antimicrobial activity of trisodium citrate over heparin for catheter locking. Nephrol Dial Transplant. 2002 Dec;17(12):2189-95.</citation>
    <PMID>12454232</PMID>
  </reference>
  <reference>
    <citation>Michaud D, Komant T, Pfefferle P. Four percent trisodium citrate as an alternative anticoagulant for maintaining patency of central venous hemodialysis catheters: case report and discussion. Am J Crit Care. 2001 Sep;10(5):351-4.</citation>
    <PMID>11548568</PMID>
  </reference>
  <reference>
    <citation>Battistella M, Vercaigne LM, Cote D, Lok CE. Antibiotic lock: in vitro stability of gentamicin and sodium citrate stored in dialysis catheters at 37 degrees C. Hemodial Int. 2010 Jul;14(3):322-6. doi: 10.1111/j.1542-4758.2010.00440.x. Epub 2009 Mar 24.</citation>
    <PMID>20345391</PMID>
  </reference>
  <reference>
    <citation>Grudzinski A, Agarwal A, Bhatnagar N, Nesrallah G. Benefits and harms of citrate locking solutions for hemodialysis catheters: a systematic review and meta-analysis. Can J Kidney Health Dis. 2015 Apr 2;2:13. doi: 10.1186/s40697-015-0040-2. eCollection 2015.</citation>
    <PMID>25926995</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 11, 2021</study_first_submitted>
  <study_first_submitted_qc>February 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 16, 2021</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pediatric</keyword>
  <keyword>home parenteral nutrition</keyword>
  <keyword>intestinal failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Sodium Citrate</mesh_term>
    <mesh_term>Anticoagulants</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>de-identified data (demographics, outcomes) may be shared upon request</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

